LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | Linifanib | 10.0 | uM | LJP6 | 2 | J07 | 72 | hr | 1235 | 1357 | 4156 | 0.3265 | 0.0416 |
| MCF7 | Linifanib | 10.0 | uM | LJP6 | 3 | J07 | 72 | hr | 1235 | 1298 | 4156 | 0.3123 | 0.0214 |
| MCF7 | Linsitinib | 10.0 | uM | LJP5 | 1 | O19 | 72 | hr | 1235 | 1740 | 4156 | 0.4187 | 0.1728 |
| MCF7 | Linsitinib | 10.0 | uM | LJP5 | 2 | O19 | 72 | hr | 1235 | 1848 | 4156 | 0.4446 | 0.2097 |
| MCF7 | Linsitinib | 10.0 | uM | LJP5 | 3 | O19 | 72 | hr | 1235 | 2017 | 4156 | 0.4853 | 0.2676 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP5 | 1 | C19 | 72 | hr | 1235 | 455 | 4156 | 0.1095 | -0.2672 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP5 | 2 | C19 | 72 | hr | 1235 | 474 | 4156 | 0.1141 | -0.2607 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP5 | 3 | C19 | 72 | hr | 1235 | 332 | 4156 | 0.0799 | -0.3093 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP6 | 1 | C19 | 72 | hr | 1235 | 446 | 4156 | 0.1073 | -0.2703 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP6 | 2 | C19 | 72 | hr | 1235 | 344 | 4156 | 0.0828 | -0.3052 |
| MCF7 | Mitoxantrone | 10.0 | uM | LJP6 | 3 | C19 | 72 | hr | 1235 | 434 | 4156 | 0.1044 | -0.2744 |
| MCF7 | MK2206 | 10.0 | uM | LJP6 | 1 | F01 | 72 | hr | 1235 | 642 | 4156 | 0.1545 | -0.2032 |
| MCF7 | MK2206 | 10.0 | uM | LJP6 | 2 | F01 | 72 | hr | 1235 | 780 | 4156 | 0.1877 | -0.1559 |
| MCF7 | MK2206 | 10.0 | uM | LJP6 | 3 | F01 | 72 | hr | 1235 | 778 | 4156 | 0.1872 | -0.1566 |
| MCF7 | Neratinib | 10.0 | uM | LJP5 | 1 | A13 | 72 | hr | 1235 | 1148 | 4156 | 0.2762 | -0.0299 |
| MCF7 | Neratinib | 10.0 | uM | LJP5 | 2 | A13 | 72 | hr | 1235 | 1070 | 4156 | 0.2575 | -0.0566 |
| MCF7 | Neratinib | 10.0 | uM | LJP5 | 3 | A13 | 72 | hr | 1235 | 1289 | 4156 | 0.3101 | 0.0184 |
| MCF7 | Nilotinib | 10.0 | uM | LJP5 | 1 | N13 | 72 | hr | 1235 | 1724 | 4156 | 0.4148 | 0.1673 |
| MCF7 | Nilotinib | 10.0 | uM | LJP5 | 2 | N13 | 72 | hr | 1235 | 1460 | 4156 | 0.3513 | 0.0769 |
| MCF7 | Nilotinib | 10.0 | uM | LJP5 | 3 | N13 | 72 | hr | 1235 | 1716 | 4156 | 0.4129 | 0.1646 |
| MCF7 | Nintedanib | 10.0 | uM | LJP6 | 1 | H01 | 72 | hr | 1235 | 768 | 4156 | 0.1848 | -0.1600 |
| MCF7 | Nintedanib | 10.0 | uM | LJP6 | 2 | H01 | 72 | hr | 1235 | 822 | 4156 | 0.1978 | -0.1415 |
| MCF7 | Nintedanib | 10.0 | uM | LJP6 | 3 | H01 | 72 | hr | 1235 | 943 | 4156 | 0.2269 | -0.1001 |
| MCF7 | NU7441 | 10.0 | uM | LJP5 | 1 | C07 | 72 | hr | 1235 | 1520 | 4156 | 0.3657 | 0.0974 |
| MCF7 | NU7441 | 10.0 | uM | LJP5 | 2 | C07 | 72 | hr | 1235 | 1608 | 4156 | 0.3869 | 0.1276 |